Most people who transition from semaglutide to tirzepatide have hit a wall of some kind, whether that wall involves stalled weight loss , persistent side effects, or simply wanting better results based on the clinical data now available
Mechanistic research has converged on the VEGF signalling axis
Brand GLP-1s The current regulatory environment around compounded semaglutide and tirzepatide, including the FDA shortage resolution and the practical implications for your practice
Rosen RC, Cappelleri JC, Gendrano N
For a deeper overview of adverse effects and precautions, see our editorial on Humalog Side Effects for concise safety context you can reference before appointments
The Food and Drug Administration (FDA) has warned the public about taking unapproved versions of weight-loss drugs that do not undergo the FDAs review for safety, effectiveness, and quality before they are marketed